Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Enoxaparin Sodium Injection passes EU DCP review

Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that the company recently received notice from the Croatian Agency for Medicinal Products and Medical Devices (HALMED) of the conclusion of the Decentralised Procedure (DCP), and that the company's Enoxaparin Sodium Injection has passed the review by the Croatian Agency for Medicinal Products and Medical Devices. The drug is used to prevent venous thromboembolic disease and to treat established deep vein thrombosis, among other indications. The passing of the EU Croatian DCP review for Enoxaparin Sodium Injection is an important milestone in the company's international registration of this product. If marketing authorization issued by the relevant member states is subsequently obtained smoothly, it will help enhance the product's brand image and bring a certain positive impact on the company's expansion into overseas markets.